CRISPR Therapeutics AG (CRSP) News
Filter CRSP News Items
CRSP News Results
|Loading, please wait...|
CRSP News Highlights
- For CRSP, its 30 day story count is now at 34.
- Over the past 29 days, the trend for CRSP's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
- CAS, EDIT and PHR are the most mentioned tickers in articles about CRSP.
Latest CRSP News From Around the Web
Below are the latest news stories about CRISPR Therapeutics AG that investors may wish to consider to help them evaluate CRSP as an investment opportunity.
Genome Editing Market Size To Reach USD 15072.3 Million by 2025 | Top Key Players Sangamo Therapeutics, ToolGen, Vertex, CRISPR Therapeutics, Precision Biosciences, Oxford Genetics
Global Genome Editing Market is valued at USD 5052.2 Million in 2020 and expected to reach USD 15072.3 Million by 2025 with the CAGR of 16.9% over the forecast period. Global Genome Editing Market: Global Size, Trends, Competitive, Historical & Forecast
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $117.81, moving +0.48% from the previous trading session.
The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
A key reason why many people invest in biotech companies is that they expect them to grow much larger. Here's why they chose BioNTech (NASDAQ: BNTX), CRISPR Therapeutics (NASDAQ: CRSP), and Gritstone Bio (NASDAQ: GRTS). Zhiyuan Sun (BioNTech): In the past year, BioNTech shares have more than quintupled on investor enthusiasm surrounding its coronavirus vaccine, Comirnaty, developed jointly with Pfizer (NYSE: PFE).
Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market.
One of the pioneers of CRISPR gene editing research, Feng Zhang, recently achieved a breakthrough in how CRISPR therapies can be delivered to cells. In this Motley Fool Live video recorded on Sept. 1, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss Zhang's achievement and what it could mean for Beam.
Cathie Wood and her funds are generating a lot of interest among investors for smart picks, and these Cathie Wood stocks are worth a look.
CRISPR Therapeutics AG (CRSP) closed at $120.74 in the latest trading session, marking a -0.59% move from the prior day.